These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37305823)

  • 1. Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.
    Al-Hussaniy HA; Alburghaif AH; Alkhafaje Z; Al-Zobaidy MAJ; Alkuraishy HM; Mostafa-Hedeab G; Azam F; Al-Samydai AM; Al-Tameemi ZS; Naji MA
    J Med Life; 2023 Apr; 16(4):491-500. PubMed ID: 37305823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.
    Monahan DS; Flaherty E; Hameed A; Duffy GP
    Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
    de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
    Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
    Keshavarzian E; Sadighpour T; Mortazavizadeh SM; Soltani M; Motevalipoor AF; Khamas SS; Moazen M; Kogani M; Amin Hashemipour SM; Hosseinpour H; Valizadeh R
    Rev Recent Clin Trials; 2023; 18(2):112-122. PubMed ID: 36803186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
    Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimizing cardiac toxicity in children with acute myeloid leukemia.
    Narayan HK; Getz KD; Leger KJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
    Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
    Cells; 2023 May; 12(9):. PubMed ID: 37174712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Chemotherapy Induced Cardiomyopathy.
    Payne DL; Nohria A
    Curr Heart Fail Rep; 2017 Oct; 14(5):398-403. PubMed ID: 28779279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
    Bhagat A; Kleinerman ES
    Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.
    Conway A; McCarthy AL; Lawrence P; Clark RA
    BMC Cancer; 2015 May; 15():366. PubMed ID: 25948399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of cardiotoxicity among survivors of childhood cancer.
    Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
    Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer.
    Macedo AVS; Hajjar LA; Lyon AR; Nascimento BR; Putzu A; Rossi L; Costa RB; Landoni G; Nogueira-Rodrigues A; Ribeiro ALP
    JACC CardioOncol; 2019 Sep; 1(1):68-79. PubMed ID: 34396164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Corremans R; Adão R; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):204-215. PubMed ID: 30244497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.